Chenxiong Le Selected Research

Ceftriaxone (Ceftriaxon)

1/2020	Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone.
1/2019	Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chenxiong Le Research Topics

Disease

2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2020 - 01/2019
1	Pneumonia (Pneumonitis) 01/2019
1	Clostridium Infections 01/2019
1	Infections 01/2019
1	Polymyositis 01/2014
1	Dermatomyositis (Dermatopolymyositis) 01/2014
1	Myositis (Idiopathic Inflammatory Myopathies) 01/2014
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/2011
1	Asthma (Bronchial Asthma) 02/2011
1	Myocardial Infarction 03/2010
1	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2010

Drug/Important Bio-Agent (IBA)

4	Monoclonal AntibodiesIBA 01/2014 - 03/2010
3	sifalimumabIBA 01/2014 - 03/2010
2	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2020 - 01/2019
1	LactamsIBA 01/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2019
1	Interferon Type IIBA 11/2011
1	InterferonsIBA 11/2011
1	enokizumabIBA 02/2011
1	Interferon-alpha (Interferon Alfa)IBA 03/2010

Therapy/Procedure

1	Aftercare (After-Treatment) 01/2019